University School of Management and Entrepreneurship, Delhi Technological University, Delhi, India.
Breast Cancer Res Treat. 2021 Jun;187(2):557-567. doi: 10.1007/s10549-020-06083-6. Epub 2021 Jan 30.
This study aims to examine the burden of breast cancer in 185 countries in 2018.
The estimates of incidence, mortality, and prevalence of breast cancer were drawn from GLOBOCAN 2018. The overall burden of breast cancer was gauged using breast cancer burden index (BRCBI)-a novel index comprising age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), mortality-to-incidence ratio (MIR), prevalence-to-incidence ratio (PIR), and prevalence-to-mortality ratio (PMR). The socioeconomic status of countries was measured using human development index (HDI) RESULTS: Globally, breast cancer was responsible for an estimated 626,679 deaths at age-standardized rate of 13/100,000; there were 2.1 million cases diagnosed in 2018 at age-standardized rate of 46.3/100,000. The ASIR varied 22-fold from 5/100,000 (Bhutan) to 113.2/100,000 (Belgium). The ASMR varied 13-fold from 2.7/100,000 (Bhutan) to 36.9/100,000 (Fiji). The HDI exhibited a positive gradient with ASIR (r = 0.73), PIR (r = 0.98), and PMR (r = 0.85); with MIR, however, it exhibited a negative association (r = - 0.83). The BRCBI spanned from 0.70 in Somalia to 78.92 in South Korea and exhibited a positive association with HDI (r = 0.76). An additional 46,823 female lives in 2018 and a cumulative total of 333,304 lives could have been saved over 2013-2018, had countries performed as per their HDI.
The substantial burden of breast cancer in developing and low-resource economies calls for a holistic approach to cancer management and control that includes oncologic infrastructure to provide cost-effective screening, diagnostic, therapeutic, and palliative services, greater breast cancer awareness, and mitigation of risk factors.
本研究旨在评估 2018 年 185 个国家/地区的乳腺癌负担。
使用 GLOBOCAN 2018 数据估计乳腺癌的发病率、死亡率和患病率。采用乳腺癌负担指数（BRCBI）来评估乳腺癌的总体负担，该指数由年龄标准化发病率（ASIR）、年龄标准化死亡率（ASMR）、死亡率与发病率比（MIR）、患病率与发病率比（PIR）和患病率与死亡率比（PMR）组成。使用人类发展指数（HDI）衡量各国的社会经济地位。
全球范围内，乳腺癌导致年龄标准化死亡率为 13/100,000，估计有 626,679 人死亡；2018 年诊断出 210 万人，年龄标准化发病率为 46.3/100,000。ASIR 差异高达 22 倍，从 5/100,000（不丹）到 113.2/100,000（比利时）。ASMR 差异达 13 倍，从 2.7/100,000（不丹）到 36.9/100,000（斐济）。HDI 与 ASIR（r=0.73）、PIR（r=0.98）和 PMR（r=0.85）呈正相关，但与 MIR 呈负相关（r=-0.83）。BRCBI 从索马里的 0.70 到韩国的 78.92 不等，与 HDI 呈正相关（r=0.76）。如果各国按照其人类发展指数表现，2018 年将有额外的 46,823 名女性死亡，在 2013-2018 年期间，将总共可挽救 333,304 条生命。
发展中国家和资源匮乏经济体的乳腺癌负担沉重，需要采取整体方法来管理和控制癌症，包括肿瘤学基础设施，以提供具有成本效益的筛查、诊断、治疗和姑息治疗服务，提高乳腺癌的认识，并减轻风险因素。
